Mankind Pharma Limited (MANKIND)
Press Release
Press Release - Q2FY27
- Revenue 4,338 Cr +17.3% y-y; EBITDA 1,175 Cr +27.2% y-y (margin 27.1%, +210 bps); PAT 716 Cr +37.7% y-y (margin 16.5%, +240 bps)
- Domestic business grew 15.9% with 1.2x volume outperformance to IPM; strong chronic and acute segment growth
- International business up 33%; Consumer Healthcare growth muted but market share gains in key brands
- EBITDA margin improved by 210 bps to 27.1% driven by disciplined execution
- Acquisition of Armed Cell Therapeutics strengthens R&D in Next-Gen CAR-T therapies
- H1 FY27 revenue 8,368 Cr +15.1%, EBITDA 2,235 Cr +26%, PAT 1,290 Cr +33.7%
- Earnings call scheduled on 26 Oct 2026 at 5:00 pm IST
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 MANKIND — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add MANKIND to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Mankind Pharma Limited
Important.
The summary above is generated automatically from Mankind Pharma Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.